Brett A. Grimaud's Net Worth
$2.76 Million
Who is Brett A. Grimaud?
Brett A. Grimaud has an estimated net worth of $2.76 Million. This is based on reported shares in Theravance Biopharma, Inc..
SEC CIK
Brett A. Grimaud's CIK is 0001966698
Past Insider Trading and Trends
2023 was Brett A. Grimaud's most active year for acquiring shares with 1 total transactions. Brett A. Grimaud's most active month to acquire stocks was the month of February. 2023 was Brett A. Grimaud's most active year for disposing of shares, totalling 4 transactions. Brett A. Grimaud's most active month to dispose stocks was the month of January. 2023 saw Brett A. Grimaud paying a total of $0.00 for 75,000 shares, this is the most they've acquired in one year. In 2023 Brett A. Grimaud cashed out on 37,942 shares for a total of $397,835.32, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Theravance Biopharma, Inc. (TBPH) Snapshot price: $8.505
SVP, GEN COUNSEL AND SECRETARY
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.57% | -9.27K |
$9.10 | -$84,338.80 | 351.88K |
May 20
| |||
Form 4
| +38.36% | 100K |
—
|
—
| 360.68K |
Apr 2
| |||
Form 4
| -6.32% | -17.59K |
$8.92 | -$156,947.40 | 260.68K |
Feb 20
| |||
Form 4
| -2.58% | -7.36K |
$10.37 | -$76,354.31 | 278.28K |
Nov 20
| |||
Form 4
| -3.03% | -8.91K |
$9.70 | -$86,446.40 | 285.3K |
Aug 20
| |||
Form 4
| -3.75% | -11.47K |
$11.21 | -$128,567.49 | 294.21K |
May 20
| |||
Form 4
| +32.61% | 75K |
—
|
—
| 304.96K |
Mar 1
| |||
Form 4
| -4.25% | -10.20K |
$10.44 | -$106,467.12 | 229.96K |
Feb 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||